AEON Biopharma, Inc. (AEON) stock
AEONNYSEPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 4/30
$0.12+0.01 (+9.61%)
Close on Nov 18, 2026Market cap $6.20MP/E –Yield –
AEON Biopharma operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
AEON Biopharma's operating income for the twelve months ending Jun 30, 2026 was -$19.86M. For fiscal 2025 it was -$12.80M, down 117.5% from the year before.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$12.80M | -117.5% |
| FY2024 | Dec 31, 2024 | $72.99M | – |
| FY2022 | Dec 31, 2022 | -$48.43M | – |
| FY2021 | Dec 31, 2021 | -$1.94M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$5.92M | – |
| Q1 FY2026 | Mar 31, 2026 | -$5.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.51M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.49M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.34M | -102.8% |
| Q1 FY2025 | Mar 31, 2025 | -$462.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.32M | – |
| Q3 FY2024 | Sep 30, 2024 | -$4.02M | – |
| Q2 FY2024 | Jun 30, 2024 | $153.47M | – |
| Q1 FY2024 | Mar 31, 2024 | -$74.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.97M | – |
| Q1 FY2023 | Mar 31, 2023 | -$13.05M | – |
| Q4 FY2022 | Dec 31, 2022 | -$15.03M | – |
| Q3 FY2022 | Sep 30, 2022 | -$9.91M | – |
| Q2 FY2022 | Jun 30, 2022 | -$427.20K | – |
| Q1 FY2022 | Mar 31, 2022 | -$389.07K | – |
| Q4 FY2021 | Dec 31, 2021 | -$885.74K | – |
| Q3 FY2021 | Sep 30, 2021 | -$450.89K | – |
| Q2 FY2021 | Jun 30, 2021 | -$398.44K | – |
| Q1 FY2021 | Mar 31, 2021 | -$200.86K | – |
See a number that looks wrong?